SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ma, Shuang ^a   Yang, Ling Ling ^a   Niu, Ting ^a   Cheng, Chuan ^a   Zhong, Lei ^a   Zheng, Ming Wu ^a   Xiong, Yu ^a   Li, Lin Li ^a   Xiang, Rong ^b   Chen, Li Juan ^a   Zhou, Qiao ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1-(4-(1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-YLOXY)-3-FLUOROPHENYL)-3-(5-TERT-BUTYLISOXAZOL-3-YL)UREA; 1-(4-(1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-YLOXY)PHENYL)-3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREA; ANTINEOPLASTIC AGENT; BETA CATENIN; CARBANILAMIDE DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; ISOXAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; UREA; WNT PROTEIN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; LEUKEMIA, MYELOID, ACUTE; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TRANSGENIC ANIMAL; TUMOR CELL LINE; WNT SIGNALING PATHWAY; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FMS-LIKE TYROSINE KINASE 3; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; ISOXAZOLES; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; PHENYLUREA COMPOUNDS; PYRAZOLES; PYRIMIDINES; UREA; WNT PROTEINS; WNT SIGNALING PATHWAY; ZEBRAFISH;

EID: 84945260319     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15646     Document Type: Article

References (43)

1. Estey, E. , D?ner, H. Acute myeloid leukaemia. The Lancet 368, 1894-1907 (2006).
2. Lowenberg, B. , Downing, J. R. , Burnett, A. Acute myeloid leukemia. New England Journal of Medicine 341, 1051-1062 (1999).
3. Loriaux, M. M. et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111, 4788-4796 (2008).
4. Gilliland, D. G. , Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100, 1532-1542 (2002).
5. Reindl, C. et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 107, 3700-3707 (2006).
6. Kiyoi, H. , Ohno, R. , Ueda, R. , Saito, H. , Naoe, T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21, 2555-2563 (2002).
7. Ma, H. et al. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. Blood 123, 1525-1534 (2014).
8. Swords, R. , Freeman, C. , Giles, F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 26, 2176-2185 (2012).
9. Cloos, J. et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20, 1217-1220 (2006).
10. Brown, P. et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104, 1841-1849 (2004).
11. Kindler, T. , Lipka, D. B. , Fischer, T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116, 5089-5102 (2010).
12. Sawyers, C. L. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer cell 1, 413-415 (2002).
13. Fathi, A. , Levis, M. FLT3 inhibitors: a story of the old and the new. Current opinion in hematology 18, 71 (2011).
14. Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669-3676 (2004).
15. Griswold, I. J. et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 104, 2912-2918 (2004).
16. Auclair, D. et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21, 439-445 (2007).
17. O'Farrell, A. M. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
18. Zarrinkar, P. P. et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114, 2984-2992 (2009).
19. Chu, S. H. , Small, D. Mechanisms of resistance to FLT3 inhibitors. Drug Resistance Updates 12, 8-16 (2009).
20. Weisberg, E. , Sattler, M. , Ray, A. , Griffin, J. Drug resistance in mutant FLT3-positive AML. Oncogene 29, 5120-5134 (2010).
21. Cools, J. et al. Prediction of Resistance to Small Molecule FLT3 Inhibitors Implications for Molecularly Targeted Therapy of Acute Leukemia. Cancer research 64, 6385-6389 (2004).
22. Breitenbuecher, F. et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood 113, 4063-4073 (2009).
23. Carter, B. Z. et al. Survivin is highly expressed in CD34(+ )38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120, 173-180 (2012).
24. Mony, U. , Jawad, M. , Seedhouse, C. , Russell, N. , Pallis, M. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia 22, 1395-1401 (2008).
25. Wang, Y. et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327, 1650-1653 (2010).
26. McCubrey, J. et al. Multifaceted roles of GSK-3 and Wnt/?-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 28, 15-33 (2014).
27. Yang, L.-L. et al. Structure-activity relationship studies of pyrazolo [3, 4-d] pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo. Journal of medicinal chemistry 56, 1641-1655 (2013).
28. Bellipanni, G. et al. Essential and opposing roles of zebrafish beta-catenins in the formation of dorsal axial structures and neurectoderm. Development 133, 1299-1309 (2006).
29. Weidinger, G. , Thorpe, C. J. , Wuennenberg-Stapleton, K. , Ngai, J. , Moon, R. T. The sp1-related transcription factors "sp5" and "sp5-like" act downstream of Wnt/?-catenin signaling in mesoderm and neuroectoderm patterning. Current biology 15, 489-500 (2005).
30. Wulf, G. G. et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98, 1166-1173 (2001).
31. Nievergall, E. et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood 123, 1218-1228 (2014).
32. Fiskus, W. et al. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia 29, 1267-1278 (2015).
33. Griffiths, E. A. et al. Pharmacological targeting of beta-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica 100, e49-52 (2015).
34. Yeung, J. et al. ?-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer cell 18, 606-618 (2010).
35. Pratz, K. W. , Sato, T. , Murphy, K. M. , Stine, A. , Rajkhowa, T. , Levis, M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115, 1425-1432 (2010).
36. Najdi, R. et al. A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer. Oncogene 28, 4133-4146 (2009).
37. Sakanaka, C. , Leong, P. , Xu, L. , Harrison, S. D. , Williams, L. T. Casein kinase I? in the Wnt pathway: Regulation of ?-catenin function. Proceedings of the National Academy of Sciences 96, 12548-12552 (1999).
38. Sun, T.-Q. et al. PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling. Nature cell biology 3, 628-636 (2001).
39. Billiard, J. , Way, D. S. , Seestaller-Wehr, L. M. , Moran, R. A. , Mangine, A. , Bodine, P. V. The orphan receptor tyrosine kinase Ror2 modulates canonical Wnt signaling in osteoblastic cells. Molecular endocrinology 19, 90-101 (2005).
40. Coombs, G. S. et al. WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. Journal of cell science 123, 3357-3367 (2010).
41. Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature biotechnology 23, 329-336 (2005).
42. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology 26, 127-132 (2008).
43. Zhong, L. et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB?329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer 135, 2972-2983 (2014).